Domov › Rak ledvic (renocelularni karcinom) › New York › New York City
Klinične študije za Rak ledvic (renocelularni karcinom) v New York City, NY
27 študij za Rak ledvic (renocelularni karcinom) išče udeležence na lokacijah v New York City in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Vključevanje udeležencevFaza 1
- Research Site, New York
- Research Site, New York
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Vključevanje udeležencevFaza 1
- NEO-811 NYC Site, New York
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Vključevanje udeležencevFaza 1/2
- Laura and Isaac Perlmutter Cancer Center ( Site 5016), New York
- Memorial Sloan Kettering Cancer Center ( Site 5002), New York
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Vključevanje udeležencevFaza 1
- Memorial Sloan Kettering Cancer Center, New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Vključevanje udeležencevFaza 1
- Exelixis Clinical Site #60, New York
- Exelixis Clinical Site #6, New York
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Vključevanje udeležencevFaza 2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Vključevanje udeležencevOpazovalna študija
- NYU Langone Medical Center, New York
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Vključevanje udeležencevFaza 3
- Memorial Sloan Kettering Cancer Center ( Site 0126), New York
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Vključevanje udeležencevFaza 1/2
- Memorial Sloan Kettering Cancer Center, New York
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
Vključevanje udeležencevFaza 2
- Columbia University Irving Medical Center, New York
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Vključevanje udeležencevFaza 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Manhattan Eye Ear and Throat Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
- in še 1
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Vključevanje udeležencevFaza 1/2
- Icahn School of Medicine at Mount Sinai, New York
- Evelyn H. Lauder Breast and Imaging Center (BAIC), New York
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
- in še 1
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Vključevanje udeležencevFaza 1
- Memorial Sloan Kettering Cancer Center, New York
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Tisch Cancer Institute (TCI), Icahn School of Medicine, New York
- Columbia University, New York
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Vključevanje udeležencevFaza 3
- Mount Sinai Chelsea, New York
- Mount Sinai Hospital, New York
- Manhattan Eye Ear and Throat Hospital, New York
- in še 2
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Vključevanje udeležencev
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Vključevanje udeležencevFaza 1
- New York Cancer & Blood Specialists, New York
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Vključevanje udeležencevFaza 1
- Memorial Sloan Kettering Cancer Center, New York
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Vključevanje udeležencevFaza 1
- Xencor Investigative Site, New York
- Xencor Investigative Site, New York
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Vključevanje udeležencevFaza 1/2
- NYU Langone Health Perlmutter Cancer Center, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University - The Trustees of Columbia University in the City of New York, New York
- in še 1
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Vključevanje udeležencevFaza 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Vključevanje udeležencevFaza 1
- NYU Laura and Isaac Perlmutter Cancer Center - 34th Street /ID# 257869, New York
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
Vključevanje udeležencevFaza 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
Decision Aid (DA) for Renal Patients
Vključevanje udeležencev
- NYU Langone Health, New York
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Vključevanje udeležencevFaza 1/2
- NYU Langone Health, New York
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Vključevanje udeležencevFaza 1/2
- Memorial Sloan-Kettering Cancer Center, New York
Študije za Rak ledvic (renocelularni karcinom) v drugih mestih
- Houston, TX35 študij
- Nashville, TN23 študij
- Dallas, TX23 študij
- St. Louis, MO23 študij
- Los Angeles, CA20 študij
- Boston, MA16 študij
- Baldwin Park, CA16 študij
- Philadelphia, PA15 študij
- Pittsburgh, PA15 študij
- Queens, NY15 študij
- Rochester, MN14 študij
- Cleveland, OH14 študij
Druge študije v New York City
- Rak dojke136 študij
- Nemalicelični pljučni rak121 študij
- Rak (vse vrste)109 študij
- Rak prostate103 študij
- Metastatski rak93 študij
- Kolorektalni rak78 študij
- Rak jajčnikov69 študij
- Rak pljuč60 študij
- Množni mielom60 študij
- Rak trebušne slinavke60 študij
- Rak endometrija52 študij
- Akutna mieločna levkemija51 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.